French drama over sovereign paracetamol is really about a deeper ailment: underinvestment.

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

Sanofi agrees to sell a 50% stake in Opella to CDR for €15bn, securing job promises. Discover the impact on France ...

Global investment firm CD&R announced an open offer to buy a 26% stake in Sanofi Consumer Healthcare India for Rs 2,983 crore ...

French drugmaker Sanofi's confirmation that it will sell a controlling stake in its consumer health unit to a US investment ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target ...

Sanofi and private equity firm CD&R are in negotiations to sell a 50% stake in Opella, Sanofi's consumer healthcare division. With a €16B valuation, Opella is the third-largest player in the global ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...